Adedoyin A - Search Results

1

Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer.

Persad R, Fleming C, Chern HD, Lesnick T, Collins C, Smith P, Schwartz AG, Adedoyin A, Romkes M, Wilkinson GR, Branch RA. Persad R, et al. Among authors: adedoyin a. Urol Oncol. 1997 Jan-Feb;3(1):18-26. doi: 10.1016/s1078-1439(97)00019-7. Urol Oncol. 1997. PMID: 21227048

2

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.

Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, Wilkinson GR, Fleming CM, Dickinson AJ, Sibley G, et al. Branch RA, et al. Among authors: adedoyin a. Pharmacogenetics. 1995;5 Spec No:S97-102. doi: 10.1097/00008571-199512001-00009. Pharmacogenetics. 1995. PMID: 7581498 Review.

3

Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer.

Fleming CM, Persad R, Kaisary A, Smith P, Adedoyin A, Porter J, Wilkinson GR, Branch RA. Fleming CM, et al. Among authors: adedoyin a. Pharmacogenetics. 1994 Aug;4(4):199-207. doi: 10.1097/00008571-199408000-00004. Pharmacogenetics. 1994. PMID: 7987404

4

Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes.

Irshaid Y, Adedoyin A, Lotze M, Branch RA. Irshaid Y, et al. Among authors: adedoyin a. Drug Metab Dispos. 1994 Jan-Feb;22(1):161-4. Drug Metab Dispos. 1994. PMID: 8149877

5

Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.

Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Bluhm RE, et al. Among authors: adedoyin a. Clin Pharmacol Ther. 1999 Jun;65(6):598-605. doi: 10.1016/S0009-9236(99)90081-4. Clin Pharmacol Ther. 1999. PMID: 10391665

6

Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes.

Irshaid Y, Branch RA, Adedoyin A. Irshaid Y, et al. Among authors: adedoyin a. Drug Metab Dispos. 1996 Feb;24(2):164-171. Drug Metab Dispos. 1996. PMID: 8742227

7

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.

Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Adedoyin A, et al. Clin Pharmacol Ther. 1998 Jul;64(1):8-17. doi: 10.1016/S0009-9236(98)90017-0. Clin Pharmacol Ther. 1998. PMID: 9695714 Clinical Trial.

8

In vivo modulation of CYP enzymes by quinidine and rifampin.

Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. Branch RA, et al. Among authors: adedoyin a. Clin Pharmacol Ther. 2000 Oct;68(4):401-11. doi: 10.1067/mcp.2000.110561. Clin Pharmacol Ther. 2000. PMID: 11061580

9

CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.

Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M. Carcillo JA, et al. Among authors: adedoyin a. Res Commun Mol Pathol Pharmacol. 1996 Feb;91(2):149-159. Res Commun Mol Pathol Pharmacol. 1996. PMID: 8832907 Clinical Trial.

10

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.

Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Frye RF, et al. Among authors: adedoyin a. Clin Pharmacol Ther. 1997 Oct;62(4):365-76. doi: 10.1016/S0009-9236(97)90114-4. Clin Pharmacol Ther. 1997. PMID: 9357387 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters